Results 21 to 30 of about 127,348 (379)

Evaluation of neutropenia secondary to mycophenolate mofetil associated with valganciclovir in liver transplant patients [PDF]

Farmacia Hospitalaria, 2021
Objective: Immunosuppressive drugs are necessary to avoid or reduce the risk of rejection of transplanted organs. The immunosuppression generated may result in these patients needing antibiotics and antivirals to be prescribed to them in conjunction ...
Alejandro Ferrer-Machín, Martín Vera-Cabrera, Inmaculada Plasencia-García, Antonia Moreno-García, Lina I. Pérez-Méndez, Javier Merino-Alonso   +5 more
doaj   +1 more source

Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis

Kidney International Reports, 2022
Introduction: Addition of a calcineurin inhibitor (CNI) to corticosteroids and mycophenolate increased the renal response rate in lupus nephritis (LN) because of proteinuria reduction, but there is little long-term efficacy and safety data on this triple
Desmond Y.H. Yap, Philip Hei Li, Colin Tang, Benjamin Y.F. So, Lorraine P.Y. Kwan, Gary C.W. Chan, Chak Sing Lau, Tak Mao Chan   +7 more
doaj   +1 more source

Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. [PDF]

, 2015
Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy in a SLE patient who is already leukopenic is a clinical concern. It could worsen leukopenia, increase the risk of infection, or both. The aim of this study was to analyze
Magder, Laurence S., Petri, Michelle, Subedi, Ananta   +2 more
core   +2 more sources

Outcome of therapy in biopsy proven lupus nephritis with cyclophosphamide or mycophenolate: Registry data from a South Indian tertiary care center

Indian Journal of Rheumatology, 2017
Background: Cyclophosphamide and mycophenolate are the currently proposed first-line agents for induction in lupus nephritis (LN). In this study, we analysed the response rates with the three different induction regimens currently available for LN ...
Keerthi Talari, Rajendra Varaprasad Irlapati, Megha Uppin, Liza Rajasekhar   +3 more
doaj   +1 more source

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. [PDF]

, 2012
OBJECTIVE: A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset.
Jimenez, Sergio A., Lee, MD, Jason B., Mendoza, MD, Fabian A., Nagle, Sarah J.   +3 more
core   +3 more sources

Mycophenolate Mofetil in C3 Glomerulopathy and Pathogenic Drivers of the Disease.

American Society of Nephrology. Clinical Journal, 2020
BACKGROUND AND OBJECTIVES C3 glomerulopathy is a complement-mediated disease arising from abnormalities in complement genes and/or antibodies against complement components.
F. Caravaca-Fontán, M. Díaz-Encarnación, Laura Lucientes, T. Cavero, V. Cabello, G. Ariceta, L. Quintana, H. Marco, X. Barros, N. Ramos, N. Rodríguez-Mendiola, Sonia Cruz, G. Fernández-Juárez, Adela Rodríguez, A. Pérez de José, C. Rabasco, R. Rodado, L. Fernández, V. Pérez Gómez, A. Ávila, Luis Bravo, J. Lumbreras, N. Allende, M. D. Sánchez de la Nieta, E. Rodríguez, T. Olea, M. Melgosa, A. Huerta, R. Miquel, C. Mon, G. Fraga, A. de Lorenzo, J. Draibe, Marta Cano-Megías, Fayna González, A. Shabaka, Maria Esperanza López-Rubio, M. Fenollosa, Luis Martín-Penagos, Iara Da Silva, Juana Alonso Titos, S. Rodríguez de Córdoba, E. Goicoechea de Jorge, M. Praga   +43 more
semanticscholar   +1 more source

Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis

Frontiers in Pharmacology, 2022
Background: A significant proportion of lupus nephritis patients develop chronic kidney disease (CKD) and progressive kidney fibrosis, for which there is no specific treatment.
Chenzhu Zhang, Tsz Wai Tam, Mel KM Chau, Cristina Alexandra García Córdoba, Susan Yung, Tak Mao Chan   +5 more
doaj   +1 more source

Nintedanib for systemic sclerosis–associated interstitial lung disease [PDF]

, 2019
BackgroundInterstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects ...
Alves, Margarida, Azuma, Arata, Clerisme-Beaty, Emmanuelle, Distler, Oliver, Fischer, Aryeh, Gahlemann, Martina, Girard, Mannaig, Highland, Kristin B., Kuwana, Masataka, Maher, Toby M., Mayes, Maureen D., Raghu, Ganesh, Sauter, Wiebke, SENSCIS Trial Investigator, for the, Smith, Vanessa, Stowasser, Susanne, Tetzlaff, Kay   +16 more
core   +3 more sources

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

ACR Open Rheumatology, 2020
Our objective was to determine if treatment with cyclophosphamide (CYC) and mycophenolate mofetil (MMF) improves patient‐reported outcomes (PROs) among patients with systemic sclerosis‐related interstitial lung disease (SSc‐ILD).
E. Volkmann, D. Tashkin, H. LeClair, M. Roth, G. Kim, J. Goldin, P. Clements, D. Furst, D. Khanna   +8 more
semanticscholar   +1 more source

Mycophenolate Improves Brain–Gut Axis Inducing Remodeling of Gut Microbiota in DOCA-Salt Hypertensive Rats

Antioxidants, 2020
Microbiota is involved in the host blood pressure (BP) regulation. The immunosuppressive drug mofetil mycophenolate (MMF) ameliorates hypertension. The present study analyzed whether MMF improves dysbiosis in mineralocorticoid-induced hypertension.
Iñaki Robles-Vera, Néstor de la Visitación, Manuel Sánchez, Manuel Gómez-Guzmán, Rosario Jiménez, Javier Moleón, Cristina González-Correa, Miguel Romero, Tao Yang, Mohan K. Raizada, Marta Toral, Juan Duarte   +11 more
doaj   +1 more source